

CLAIMS

1. A method of treating or preventing warm autoimmune hemolytic anemia in a patient in need thereof, comprising administering to the patient: (i) a therapeutically effective amount of an anti-FcRn antibody or an antigen-binding fragment thereof; or (ii) a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a therapeutically effective amount of an anti-FcRn antibody or an antigen-binding fragment thereof, wherein:

the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 27 (HCDR1), an amino acid sequence of SEQ ID No: 28 (HCDR2), and an amino acid sequence of SEQ ID No: 29 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 30 (LCDR1), an amino acid sequence of SEQ ID No: 31 (LCDR2), and an amino acid sequence of SEQ ID No: 32 (LCDR3); or

the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 21 (HCDR1), an amino acid sequence of SEQ ID No: 22 (HCDR2), and an amino acid sequence of SEQ ID No: 23 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 24 (LCDR1), an amino acid sequence of SEQ ID No: 25 (LCDR2), and an amino acid sequence of SEQ ID No: 26 (LCDR3); and

the therapeutically effective amount of the antibody or antigen-binding fragment is about 170 mg to about 1500 mg.

2. The method of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 27

(HCDR1), an amino acid sequence of SEQ ID No: 28 (HCDR2), and an amino acid sequence of SEQ ID No: 29 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 30 (LCDR1), an amino acid sequence of SEQ ID No: 31 (LCDR2), and an amino acid sequence of SEQ ID No: 32 (LCDR3).

3. The method of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 21 (HCDR1), an amino acid sequence of SEQ ID No: 22 (HCDR2), and an amino acid sequence of SEQ ID No: 23 (HCDR3); and a light chain variable region comprising an amino acid sequence of SEQ ID No: 24 (LCDR1), an amino acid sequence of SEQ ID No: 25 (LCDR2), and an amino acid sequence of SEQ ID No: 26 (LCDR3).
4. The method of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 4 or SEQ ID No: 6; and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 14 or SEQ ID No: 16.
5. The method of claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID No: 2; and a light chain variable region comprising an amino acid sequence of SEQ ID No: 12.
6. The method of claim 1, wherein the antibody or antigen-binding fragment binds to FcRn with a K_D (dissociation constant) of 0.01 nM to 2 nM at pH 6.0 or pH 7.4.

7. The method of claim 6, wherein the K_D is measured by surface plasmon resonance (SPR).
8. The method of claim 1, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered subcutaneously.
9. The method of claim 1, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered as one or more subcutaneous injections.
10. The method of claim 9, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered without intravenous administration prior to the one or more subcutaneous injections.
11. The method of claim 1, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered once as a single dose or once weekly.
12. The method of claim 1, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is 170 mg to 300 mg.
13. The method of claim 1, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is 300 mg to 500 mg.
14. The method of claim 1, wherein the therapeutically effective amount of the antibody

or antigen-binding fragment is 500 mg to 700 mg.

15. The method of claim 1, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is 700 mg to 900 mg.
16. The method of claim 1, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is 900 mg to 1100 mg.
17. The method of claim 1, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is 1100 mg to 1300 mg.
18. The method of claim 1, wherein the therapeutically effective amount of the antibody or antigen-binding fragment is 1300 mg to 1500 mg.
19. The method of claim 1, wherein the antibody, antigen-binding fragment, or pharmaceutical composition is administered in combination with at least one additional therapeutic agent.